In this sense, in the neo-ALTTO trial, a 41-gene expression signature called the Trastuzumab Risk model (TRAR) signature has been identified as a predictor of response to anti-HER2 therapies in HER2-positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.